Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.45 |
| ▸ | GRN | P28799 | 2/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8017457 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL15757059 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL30544338 | 0.94 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL29883433 | 0.90 | MME (0.47) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL30808873 | 0.90 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL11127918 | 0.89 | ALDH1A1 (0.49) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL3873046 | 0.88 | ALDH1A1 (0.45) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL6517513 | 0.88 | OPRM1 (0.45) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL65868 | 0.88 | ALDH1A1 (0.62) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL29148902 | 0.88 | ALDH1A1 (0.62) | ALDH1A1MAPTMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680261-A1 | PRODUCTS AND METHODS FOR TREATING METABOLIC, CARDIOVASCULAR, INFLAMMATORY AND ONCOLOGICAL DISEASES | The Regents Of The University Of Michigan (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024192564-A1 | PRODUCTS AND METHODS FOR TREATING METABOLIC, CARDIOVASCULAR, INFLAMMATORY AND ONCOLOGICAL DISEASES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20230181673-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| US-20180074053-A1 | TREATMENT OF DIABETES USING AGONISTS OF THE MAS-RELATED GPCR D | DIAPIN THERAPEUTICS LLC | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180074053-A1 | TREATMENT OF DIABETES USING AGONISTS OF THE MAS-RELATED GPCR D | GPR119, MRGPRX2, MRGPRX1 | ALDH1A1 3945/4885MAPT 4643/4885MEN1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.